Cerluten
Cerluten (Glu-Asp-Pro) is a Khavinson synthetic tripeptide bioregulator for the nervous system. Proposed to support neuronal gene regulation and nervous system aging. Used in Eastern European anti-aging longevity protocols.
Community Rating
No ratings yet
Compound Profile
Cerluten
Key Data
Research reference only
Research Focus
Preclinical data
⚠ Research & Educational Use Only. Cerluten is a research chemical documented here for scientific education. All information references peer-reviewed literature and preclinical/clinical study data. Not for human consumption. Not medical advice. Consult a licensed researcher or healthcare professional before any laboratory use.
- Proposed to regulate gene expression in nervous system tissue via the Khavinson short peptide bioregulator mechanism
- May support neuronal maintenance and reduce age-associated nervous system dysfunction
- Distinct from Crystagen (Glu-Asp-Arg) in C-terminal residue — different proposed chromatin interaction profile
- Cerluten is not FDA-approved for human use. It is a research chemical for scientific study only.
Research At a Glance
- Proposed to regulate gene expression in nervous system tissue via the Khavinson short peptide bioregulator mechanism
- May support neuronal maintenance and reduce age-associated nervous system dysfunction
- Distinct from Crystagen (Glu-Asp-Arg) in C-terminal residue — different proposed chromatin interaction profile
- Used in comprehensive anti-aging protocols targeting multiple organ systems simultaneously
In Plain English
Simple summaryCerluten is a synthetic polypeptide preparation from the Khavinson bioregulator series targeted at the nervous system -- specifically the cerebral cortex. Like Endoluten (pineal) and the other complex preparations in the Cytomaxes line, Cerluten is a peptide complex derived from brain cortex tissue rather than a single defined sequence. It's proposed to restore gene expression in neurons, support cognitive function, and provide neuroprotection in aging. The Khavinson group positions it as a neural restoration bioregulator similar in concept to Cortagen (the defined cortical tetrapeptide) but as a broader peptide complex.
- Proposed to regulate gene expression in nervous system tissue via the Khavinson short peptide bioregulator mechanism
- May support neuronal maintenance and reduce age-associated nervous system dysfunction
- Distinct from Crystagen (Glu-Asp-Arg) in C-terminal residue — different proposed chromatin interaction profile
The full scientific detail, mechanisms, citations, and dosing data, follows below.
What is Cerluten?
Tap any underlined term for an instant definition.
Cerluten is a synthetic tripeptide (Glutamic acid-Aspartic acid-Proline, Glu-Asp-Pro) belonging to Professor Khavinson's short peptide bioregulator family. It is formulated for the nervous system and shares the Glu-Asp dipeptide core with Crystagen (which has C-terminal Arg instead of Pro).
Like all Khavinson bioregulators, Cerluten is proposed to act as a gene-regulatory short peptide that can penetrate cell membranes and interact with DNA chromatin in a sequence-selective manner. The research framework, published primarily in Russian journals and translated works, suggests that these dipeptides and tripeptides derived from different organ tissues retain "informational" sequences that can upregulate transcription of specific genes in their target tissue.
Cerluten's proline residue vs Crystagen's arginine may alter its interaction profile with DNA promoter sequences. Proline-containing peptides have constrained conformational flexibility that may affect DNA-binding geometry and sequence selectivity in the chromatin-interaction model proposed by Khavinson.
In practice, Cerluten is used in Eastern European gerontological clinics and research protocols as part of multi-organ bioregulator stacks targeting nervous system aging, often combined with Epithalon (pineal), Thymalin (thymus), Cortagen (blood vessels), and Cartalax (cartilage) in comprehensive anti-aging protocols lasting 1-3 months.
Independent validation of the specific mechanisms claimed for Cerluten and its congeners remains limited in the Western peer-reviewed literature, though the broader peptide bioregulator field is an active area of inquiry. Computational studies of short peptide-DNA interactions provide mechanistic plausibility.
By the Numbers
Key Research Benefits
Documented effects observed in preclinical and clinical studies on Cerluten. See all Cognitive Enhancement peptides for comparison.
Side Effects & Risks
Adverse effects reported in the research literature. All data sourced from preclinical and clinical study reports. View all peptides' side effects →
Dosing Data from the Literature
Doses referenced below are sourced from published preclinical and clinical studies. Use the peptide dose calculator to convert these values to injection volume.
Based on Khavinson bioregulator protocol methodology:
Oral capsule: 10 mg twice daily for 30-day course (1-2 courses per year) SC injection (research): 1-5 mcg/kg/day × 10 days
Typically used as part of comprehensive multi-organ bioregulator protocols
Administration in Research Settings
Standard reconstitution and administration methodology for laboratory research use.
Oral or SC injection. Part of the Khavinson organ-targeted bioregulator family from St. Petersburg Institute of Bioregulation and Gerontology.
What the research doesn't show
Complex peptide preparations like Cerluten are even harder to study rigorously than defined single-sequence peptides -- there's no single trackable active compound. All the standard Khavinson evidence limitations apply, with the additional challenge that it's unclear which peptide(s) in the complex are responsible for any observed effects. Cerebrolysin is the better-studied brain peptide complex with some independent replication.
Medical Expert Videos
Physicians, researchers, and pharmacologists explain Cerluten, covering mechanisms of action, clinical context, and study findings.
Videos sourced from YouTube search. KnowYourPeptide does not endorse any individual creator. For research education only.
The Bottom Line
Cerluten has a growing body of preclinical evidence and a well-characterised safety profile in research settings. The most-studied application is: proposed to regulate gene expression in nervous system tissue via the khavinson short peptide bioregulator mechanism.
The most commonly reported side effect in research subjects is limited published clinical safety data in western literature. It is a research chemical, not approved for human use.
Frequently Asked Questions
Explore Further
Quick Reference
How It Compares
Cortagen (Ala-Glu-Asp-Pro) is the defined single-sequence equivalent for cortical tissue from the same program. Cerebrolysin is the most widely studied neuropeptide complex with actual Phase 2/3 human trial data in stroke and dementia. Semax has a clearer mechanism (BDNF upregulation through defined ACTH fragment) with more rigorous Russian clinical data than Cerluten.
Compare Cerluten side-by-sideResearch Use Only
This information is for educational research purposes only. This is not medical advice. Consult a qualified healthcare professional.